Prothena Corp Public Ltd Co has reported a significant stock transaction involving major shareholder William P. Scully. On November 17, 2026, Scully acquired 50,000 shares of the company at an average price of $8.0936 per share. This acquisition is notable as it underscores ongoing investment activity and confidence in the company’s future prospects.

Prothena Corp, listed on Nasdaq under the ticker PRTA, operates in the pharmaceutical preparations sector, categorized under SIC 2834. The company has been active in filing various reports with the SEC, including recent filings on November 5, 2026, which included a 10-Q and an 8-K.

The filing indicates that following this transaction, Scully now holds a total of 1,027,000 shares in Prothena. The shares were purchased in multiple transactions, with prices ranging from $7.9600 to $8.1700, as detailed in the filing. Scully’s ownership reflects a direct stake in the company, which may influence investor perceptions and market activity.

This acquisition may affect various stakeholders, including current investors and potential shareholders, as it signals Scully’s confidence in Prothena’s direction and performance. The pharmaceutical preparations industry is known for its volatility, and such transactions can impact stock prices and investor sentiment.

The filing does not specify what actions may follow this significant transaction, leaving the market to speculate on future developments.